ASCO GU 2024

Is "more" always better?

Cabo + IO: Interesting but not practice changing?!

BRCAAway - practice changing or hypothesis generating…

Salvage radiation with anti-androgen superior to…

Long-term dose escalation - Therapy in high-risk…

Therapy Intensification Still Neglected in mHSPC

What about the clinical benefit?

Enzalutamide therapy as option for biochemical…

Relugolix combined with androgen signaling in real word…

Localized PCa - news for radiotherapy and biochemical…

Still a difficult time for androgenic inhibitors in…

BRCAaway - PARP combination study

Insights and news for mCRPC

Higher radiation is effective in high-risk PCA

Further testing before olaparib combination

Gleason 3+3 - cancer or not?

Combination of cabozantinib & checkpoint inhibitor

Evaluating the recombination-repair mutations in…

First positive study of IO therapy in mCRPC

Cognitive function in ART treatment

Quality of life under intensive therapy

Combination NHT + PARP makes sense

Dose de-escalation in different ways

Olaparib + Arbiraterone better compared to either alone

Post-RP salvage radyoterapi hormonoterapi ile konbine…

Kombination av cabozantinib och immunterapi

Une période encore difficile pour les inhibiteurs…

Kognitiv påverkan av abirateron och enzalutamid?

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

SEPTA calismasi: Stockholm3 un multietnik hasta…

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…

Gleason 3+3 ska vi kalla de cancer eller inte?

New standard of care, but still open questions!

ADC + ICI: new data for platinum-refractory bladder…

Advances in (neo)-adjuvant treatment in urothelial…

EV as standard in 3rd line mUC

Should we start forgetting the Galsky Criteria in…

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Biomarker update

Adjuvant therapy in urothelial carcinoma : is the…

Highlights in bladder cancer at ASCO GU24

Pembrolizumab adjuvant in bladder cancer

Another success for an ICI?

EV + Pembro new first-line standard in localized…

Update M1 urothelial cancer

HER2 and bladder cancer

Perioperative adjuvant therapy in urothelial cancer

ASCO GU24 - Highlights in Bladder cancer

Update on EV-302

Terapia adyuvante perioperatoria en el cáncer de vejiga

¿Deberíamos empezar a olvidarnos de los Criterios de…

Encore un succès pour une ICI ?

Tratamiento adyuvante en cancer urotelial: ¿está…

Novedades sobre EV-302

Adjuvant therapy in kidney cancer: Is immunotherapy the…

Subcutaneous vs. intravenous application: ready for…

Trial updates at ASCO GU24: Are the follow-up data…

Long-term outcome

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

ASCO GU24 - Highlights in renal cell carcinoma

Practice changing adjuvant therapy?!

Durable effects of Ipi-Nivo

Long-term follow-up of first-line trials

Highlights in kidney cancer at ASCO GU24

Cabozantinib Plus Atezolizumab in Adrenocortical…

Belzutifan: Updates on QoL

Better QoL with Belzutifan

Perioperative treatment in renal cell carcinoma - did…

Tumorburden and outcome

Long-Term Data on NIVO+IPI in aRCC

Overall survival benefit - Pembro after surgery

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24